Safety, Pharmacokinetics and Pharmacodynamics of BMS-936559 in Severe Sepsis
A Phase 1b/2a, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-936559 in Subjects With Severe Sepsis
Sponsor: Bristol-Myers Squibb
Terminated
Business Objectives Have Changed
This PHASE1 trial investigates Septic Shock and Severe Sepsis and is currently terminated or withdrawn. Bristol-Myers Squibb leads this study, which shows 12 recorded versions since 2015 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE1
▶ Show 7 earlier versions
-
Oct 2017 — Jun 2018 [monthly]
Terminated PHASE1
Status: Active Not Recruiting → Terminated
-
Aug 2017 — Oct 2017 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jun 2017 — Aug 2017 [monthly]
Recruiting PHASE1
Phase: PHASE1_PHASE2 → PHASE1
-
Apr 2017 — Jun 2017 [monthly]
Recruiting PHASE1_PHASE2
Phase: PHASE1 → PHASE1_PHASE2
-
Mar 2017 — Apr 2017 [monthly]
Recruiting PHASE1
-
Feb 2017 — Mar 2017 [monthly]
Recruiting PHASE1
Phase: PHASE1_PHASE2 → PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Dec 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bristol-Myers Squibb
For direct contact, visit the study record on ClinicalTrials.gov .